Form 4: C4 Therapeutics Director Boosts Stake with Stock Compensation

C4 Therapeutics Director Donna Roy Grogan acquired 6,740 shares of common stock at $2.15 per share, opting for equity in lieu of cash compensation.

Summary

• Donna Roy Grogan, a Director of C4 Therapeutics, Inc. (CCCC), acquired 6,740 shares of common stock.
• The transaction occurred on October 1, 2025.
• The shares were acquired at a price of $2.15 per share, based on the closing market price on the transaction date.
• This acquisition was made pursuant to the Issuer's Non-Employee Director Compensation Policy, where Grogan elected to receive shares instead of cash for her services.
• Following this transaction, Donna Roy Grogan beneficially owns 58,629 shares of C4 Therapeutics common stock directly.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director in lieu of cash compensation is generally viewed positively as it indicates confidence in the company and aligns the director's interests with shareholders. It's a routine transaction but with a positive underlying sentiment.

Positives

• Director Donna Roy Grogan increased her direct ownership in C4 Therapeutics by acquiring 6,740 shares, signaling confidence in the company's future.
• The election to receive stock in lieu of cash compensation aligns the director's financial interests more closely with those of other shareholders.

Negatives

• No negative aspects are directly indicated by this routine insider transaction filing.

Risks

• The value of the acquired shares is subject to market fluctuations, potentially impacting the director's compensation if the stock price declines.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer.
• The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 1, 2025.

Industry Context

The practice of compensating non-employee directors with equity, either fully or partially, is a common corporate governance practice across various industries, including biotechnology, to align director interests with long-term shareholder value.

Comparison to Industry Standards

• Many publicly traded companies, particularly in the biotechnology sector like C4 Therapeutics, utilize equity compensation for non-employee directors. This aligns with broader industry trends where companies such as Moderna (MRNA) or BioNTech (BNTX) also offer stock-based compensation to their board members to foster long-term commitment and align incentives.
• The election to receive shares in lieu of cash is a standard option provided by many compensation policies, reflecting a director's belief in the company's future prospects, similar to practices seen at companies like Gilead Sciences (GILD) or Amgen (AMGN).

Corporate Governance

Related Party Transactions

• The transaction involves a director (Donna Roy Grogan) acquiring shares from the issuer (C4 Therapeutics, Inc.) as compensation, which constitutes a related party transaction under the company's Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The transaction demonstrates a director's increased stake and alignment with shareholder interests, potentially boosting investor confidence.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the reported transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a director received shares as compensation. While it indicates director confidence, it does not provide new fundamental information that would warrant a change in investment recommendation. The transaction is consistent with established compensation policies and does not suggest any significant shift in the company's operational or financial outlook.

Keywords

C4 Therapeutics, CCCC, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Equity Compensation, Donna Roy Grogan